Loading
The UK cohort of 2,915 women diagnosed with breast cancer at 40 or younger in which Black women had more triple-negative tumours (26 versus 19 percent) and worse survival despite the same access to care and the same use of chemotherapy.
Copson, Maishman, Gerty, Eccles and colleagues compared tumour pathology, treatment and outcome across ethnic groups in the POSH national cohort of women aged 40 or under at breast cancer diagnosis. Ethnicity was available for 2,915 patients: 2,690 (91.0 percent) White, 118 (4.0 percent) Black and 87 (2.9 percent) Asian. Median tumour diameter was larger in Black than White women (26.0 versus 22.0 mm, p=0.0103) and multifocal tumours more frequent in Black (43.4 percent) and Asian (37.0 percent) than White women (28.9 percent). Triple-negative tumours were more frequent in Black (26.1 percent) than White women (18.6 percent, p=0.043). Chemotherapy use was equally high (89, 88.6 and 89.7 percent). Five-year distant relapse-free survival was lower in Black women (62.8 percent) than Asian (77.0 percent, p=0.0473) or White women (77.0 percent, p=0.0053), and five-year overall survival 71.1 percent (95 percent CI 61.0 to 79.1) versus 82.4 percent (80.8 to 83.9) for White women (p=0.0160). In multivariate analysis Black ethnicity independently affected distant relapse-free survival in oestrogen receptor-positive disease (hazard ratio 1.60, 1.03 to 2.47).
The UK's own evidence that the disparity is not only American and not only about access: within the NHS, with equal chemotherapy use, young Black women had more triple-negative disease and worse survival. It anchors the disparities idea on the triple-negative page and the UK and NHS page.
Shares Ethnicity-stratified outcome reporting for triple-negative breast cancer in NHS cancer statistics, Close the gap between who gets triple-negative breast cancer and who is in its trials, Trials do not represent the people who get cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Ethnicity-stratified outcome reporting for triple-negative breast cancer in NHS cancer statistics, Close the gap between who gets triple-negative breast cancer and who is in its trials, Trials do not represent the people who get cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, Close the gap between who gets triple-negative breast cancer and who is in its trials, Trials do not represent the people who get cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares A UK audit of trial access and germline testing uptake in triple-negative breast cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares A UK audit of trial access and germline testing uptake in triple-negative breast cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares A UK audit of trial access and germline testing uptake in triple-negative breast cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares Cancer Research UK, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.